Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted radioligand therapies (RLTs).
The partnership aims to use Debiopharm’s AbYlink conjugation technology in combination with Alkyon’s modular antibody platform with a focus on undisclosed tumour-associated antigens.
Go deeper with GlobalData
It represents an advancement in the pursuit of next-generation RLTs. These therapies deliver precise radiation doses directly to cancer cells, reducing collateral damage to healthy tissue.
The synergy of both companies’ platforms could lead to tolerable options for patients suffering from challenging cancers.
Debiopharm chief scientific officer Frederic Levy stated: “We’re intrigued to explore the potential of applying AbYlink conjugation technology to the radio-oncology field.
“Leveraging our innovative conjugation platform with Alkyon’s engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDebiopharm’s AbYLink technology has regio-selective lysine conjugation capability.
This ensures that the radioligand does not interfere with the target binding site while also enabling consistent manufacturing processes.
By combining the technology with Alkyon’s antibody platform, there is potential for creating transformative cancer treatments that enhance patient quality of life.
Alkyon Therapeutics co-founder and CEO Benjamin Titz stated: “This collaboration reflects our shared commitment to expanding the potential of radioligand therapies.
“By applying AbYlink to our specialised antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumours, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumours.”
AbYlink technology ensures consistent and stable attachment at specific sites within the Fc region of an antibody or similar molecules, while preserving the integrity of antigen-binding areas.
The broad-ranging adaptability of AbYlink has been validated across different antibody isotypes and associated payloads.
